A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in pomc null mice.
Functional disruption of either MC3R or MC4R results in obesity, implicating both in the control of energy homeostasis. The ligands for these receptors are derived from the prohormone proopiomelancortin (POMC), which is posttranslationally processed to produce a set of melanocortin peptides with a range of activities at the MC3R and MC4R. The relative importance of each of these peptides alpha-MSH, gamma3-MSH, gamma2-MSH, gamma-lipotropin (gamma-LPH) and, in man but not in rodents, beta-MSH] in the maintenance of energy homeostasis is, as yet, unclear. To investigate this further, equimolar amounts (2 nmol) of each peptide were centrally administered to freely feeding, corticosterone-supplemented, Pomc null (Pomc-/-) mice. After a single dose at the onset of the dark cycle, alpha-MSH had the most potent anorexigenic effect, reducing food intake to 35% of sham-treated animals. beta-MSH, gamma-LPH, and gamma3- and gamma2-MSH all reduced food intake but to a lesser degree. The effects of peptide administration over 3 d were also assessed. Only alpha-MSH significantly reduced body weight, affecting both fat and lean mass. Other peptides had no significant effect on body weight. Pair-feeding of sham-treated mice to those treated with alpha-MSH resulted in identical changes in total weight, fat and lean mass indicating that the effects of alpha-MSH were primarily due to reduced food intake rather than increased energy expenditure. Although other melanocortins can reduce food intake in the short-term, only alpha-MSH can reduce the excess fat and lean mass found in Pomc-/- mice, mediated largely through an effect on food intake.
Tung
Y C Loraine
YC
Department of Clinical Biochemistry, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge CB2 2QR, United Kingdom.
Piper
Sarah J
SJ
Yeung
Debra
D
O'Rahilly
Stephen
S
Coll
Anthony P
AP
D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology; D001835:Body Weight / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects*; D004333:Drug Administration Routes; D004435:Eating / Q000187:drug effects*; D008297:Male; D053486:Melanocortins / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D010919:Placebos; D011333:Pro-Opiomelanocortin / Q000737:chemistry / Q000235:genetics*; D015431:Weight Loss / Q000187:drug effects; D000521:alpha-MSH / Q000494:pharmacology / Q000502:physiology
D053486:Melanocortins; D010919:Placebos; D000521:alpha-MSH; D011333:Pro-Opiomelanocortin